Elastrin Therapeutics

Antibody-targeted nanoparticle therapies for patients with vascular calcification and cardiovascular disease

Wantage, United KingdomFounded 2022elastrin.comWebsite technologies

+ Add to sales board

Highlights

  • Young companyFounded 2022
  • New on EvolcAdded 2026-11-11

About Elastrin Therapeutics

Elastrin Therapeutics is developing antibody-guided nanoparticle therapies designed to target damaged elastin and reverse vascular calcification. Its platform uses a targeting antibody, liposomal nanoparticles and adaptable therapeutic payloads.

The company works with patients and physicians through therapeutic development and seeks co-development and regional partnerships with device and pharmaceutical companies. Its stated mission is to develop therapies that restore arterial elasticity and address vascular calcification.

The registered entity is based in Wantage, United Kingdom, and the company describes itself as operating in the US and UK. Its leadership includes a co-founder and chief scientific officer affiliated with Clemson University.

Product: A preclinical platform of antibody-targeted liposomal nanoparticles designed to deliver therapies to damaged elastin and reverse vascular calcification.

Jobs at Elastrin Therapeutics

No open positions listed right now.

Leadership

More biotech & pharma companies

  • Eleventx

    Extended-release RNA medicines for chronic disease, starting in cardiometabolic, developed with pharma partners
    Cambridge, United KingdomBiotech & pharma2 open jobs
  • Ellison Institute of Technology

    Interdisciplinary research and technology institute developing commercial solutions for health, agriculture, climate and AI challenges
    Oxford, United KingdomBiotech & pharmaFounded 202174 open jobs
    Young company
  • Emstopa

    Develops an antibody-based drug to reverse tPA-induced bleeding for patients with cardiac surgery complications and major trauma
    Sandwich, United KingdomBiotech & pharmaFounded 2017
    New on Evolc
  • Enara Bio

    Cancer immunotherapies for patients with solid tumors, developed using dark-antigen discovery and T-cell engager platforms
    Oxford, United KingdomBiotech & pharmaFounded 2016
  • Engivent

    Programmable microfluidic and automation systems for biology and biotechnology research teams
    Cambridge, United KingdomBiotech & pharmaFounded 2024
    Young companyNew on Evolc
  • Enhanced Genomics

    Genomics platform and drug discovery programs for pharmaceutical partners developing therapies for human diseases
    Cambridge, United KingdomBiotech & pharmaFounded 2020
    New on Evolc

All biotech & pharma companies →

Website technologies

Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.

Content delivery

Content management

  • WixHigh confidence
    First detected
    Last detected
    Last checked
    Detection evidence

Frontend frameworks

  • ReactMedium confidence
    First detected
    Last detected
    Last checked
    Detection evidence

Monitoring

  • SentryHigh confidence
    First detected
    Last detected
    Last checked
    Detection evidence

Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.